Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2018-07-18
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies the side effects and best dose of azacitidine in treating
patients with lung cancer that is stage IV or has returned after previous treatments
(recurrent). Azacitidine is a drug used in chemotherapy that may stop tumor cells from
growing or spreading by activating genes that help prevent cancer growth, called tumor
suppressor genes. As people age, these genes are silenced by a chemical reaction that occurs
naturally in the body, or by exposure to environmental factors such as smoking. Azacitidine
may help reverse this process and restore the function of the tumor suppressor genes.
Delivering azacitidine directly into the lungs by inhalation may work better in treating lung
cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University